<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50326">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01966029</url>
  </required_header>
  <id_info>
    <org_study_id>110-502</org_study_id>
    <nct_id>NCT01966029</nct_id>
  </id_info>
  <brief_title>BMN 110 Phase 3B in Australian Patients</brief_title>
  <acronym>MOR-AUS</acronym>
  <official_title>A Multicenter Open-Label, Phase 3B Study to Evaluate the Efficacy and Safety of BMN 110 in Australian Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is currently no treatment for MPS IVA other than supportive care for the clinical
      manifestations of the disease. Enzyme replacement therapy (ERT) with BMN 110 to replace the
      deficient GALNS is a potential new treatment option for MPS IVA patients. BMN 110,containing
      recombinant human GALNS (rhGALNS) developed by BioMarin is expected to reduce the
      progressive, pathologic accumulation of KS, and improve signs and symptoms of the disease.

      The objective of this Phase 3B open label study (110-502) will be to evaluate the safety and
      tolerability of 2.0 mg/kg/week (qw) of BMN 110 in Australian patients with MPS IVA. In
      addition, a number of secondary and tertiary efficacy endpoints will also be investigated.
      The dose and regimen of BMN 110 have been selected on the basis of data from a Phase 1/2
      clinical study with BMN 110, nonclinical and in vitro studies with BMN 110, and clinical and
      nonclinical data from other enzyme replacement therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN AND PLAN: This is a multicenter, open-label Phase 3B study designed to evaluate
      the safety and efficacy of BMN 110 in Australian patients with MPS IVA. Approximately 10
      patients in Australia with a confirmed diagnosis of MPS IVA will be enrolled in this study.
      Eligible patients will receive weekly infusion of BMN 110 2.0 mg/kg for a total of 48
      consecutive weeks.

      Screening [Week -4]. After obtaining informed consent, information on
      demographics,concomitant medication(s) use and medical history (including pre-study growth
      data) will be collected; blood will be drawn for confirming MPS IVA diagnosis by enzymatic
      test (when applicable); and, blood and urine for clinical laboratory tests will be
      collected. Electrocardiogram (ECG), routine physical examination including standard
      neurological examination, vital signs; and cervical spine (flexion-extension) imaging by
      either radiographs, or a Magnetic Resonance Imaging (MRI) or CT scan may be collected during
      Screening visit. Adverse Events (AEs)/Serious Adverse Events (SAEs) will also be monitored
      and collected.

      Baseline Visit [Week 1, Day -1]. Upon confirmation of eligibility by confirmed diagnosis of
      MPS IVA by enzymatic test, negative pregnancy tests at Baseline (in women of childbearing
      age) and medical history, patients will be enrolled in the study and will complete following
      assessments: urine KS and urine creatinine, vital signs, routine physical examination
      including standard neurological examination, body weight (for verifying dose), clinical
      laboratory assessments, immunogenicity tests, ECG, 6MW test, 3MSC test and RFT will be
      performed and AEs/SAEs and concomitant medication use will be collected. In addition,
      anthropometric parameters (including height) will be measured, pain assessment
      test(Adolescent Pediatric Pain Tool [APPT], pain tool in children, adolescents, and adults)
      will be administered; and PedsQL (QOL questionnaire for pediatric patients) or SF-36 (QOL
      questionnaire for adult patients) questionnaire will also be completed during this visit.
      Patients who have abnormal overnight pulse oximetry readings will be assessed for sleep
      apnea, the results of which will be calculated using the Apnea-Hypopnea Index (AHI) at
      Baseline, Week 25 and Week 49.

      Treatment Visit 1 [Week 1, Day 1]. Patients will receive the first dose of BMN 110 by
      intravenous (IV) infusion. Assessments on Day 1 will include vital signs, routine physical
      examination including standard neurological examination, and concomitant medication use and
      AEs/SAEs. All assessments will be performed prior to treatment, except AEs/SAEs which are
      collected continuously throughout the study.

      Treatment Visits [Weeks 2-48]. Patients will be treated weekly with BMN 110 for 48 weeks.
      Prior to each weekly treatment, patients will have vital signs and routine physical
      examination including standard neurological examination. Concomitant medications and
      AEs/SAEs are collected at every visit. Body weight will be determined every 4 weeks after
      the Day -1 visit to confirm dose volume.

      Efficacy Assessment Visits [Weeks 25 and 49]. The following data will be collected during
      weeks 25 and 49: vital signs, concomitant medication use, AEs/SAEs, routine physical
      examination including standard neurological examination, clinical laboratory tests, urine KS
      and creatinine levels, urine pregnancy tests, immunogenicity test, ECG, 6MW test, 3MSC test,
      RFTs and anthropometric measurements. The patients will also complete the APPT test, and
      PedsQL or SF-36 questionnaire (as appropriate). Patients who have abnormal overnight pulse
      oximetry readings will be assessed for sleep apnea. Additional

      Safety Assessment during Week 49 Visit. In addition to the efficacy and safety assessments
      listed above, cervical spine radiographs (flexion-extension) or MRI or CT scan will also be
      collected during the Week 49 visit.

      End of Study Visit [Week 53]. The patients will be monitored for AEs and SAEs for up to 30
      days post drug infusion. During Week 53, patients will be evaluated for AEs/SAEs and will
      have vital signs taken, routine physical examination including standard neurological
      examination will be performed, and information on concomitant medication use will be
      collected.

      Patient withdrawal prior to end of study Week 53. Patients may withdraw voluntarily from
      receiving BMN 110 at any time, in which case they will be encouraged to continue to undergo
      study assessments. Data from such patients will be utilized for further characterization of
      the natural progression of MPS IVA. Patients may also withdraw entirely from complete study
      participation at any time.

      Safety The study period during which all non-serious AEs and SAEs will be reported begins
      after informed consent is obtained and through 30 days after the last study visit or 30 days
      after the last drug infusion, whichever comes first. Starting on the first Screening Day and
      continuing through the end of the study (Week 53), AEs/SAEs will be monitored and recorded,
      and routine physical examination including standard neurological examination will be
      conducted in all patients. Some patients may experience infusion associated reactions (IARs)
      associated with the administration of study drug, thus it will be required that prophylactic
      antihistamine will be administered prior to each study drug infusion. Antipyretic
      pretreatment may be given at the Investigator's discretion. The internal Data Monitoring
      Committee (DMC) will monitor the safety of BMN 110 in patients and may review any severe or
      serious IARs that occur in patients during the study. Vital signs will be measured just
      before, during, and immediately following the study drug infusion. Adverse events and
      changes in concomitant medication Safety assessments will be performed throughout the study.
      Physical examinations including neurological examination will be performed at Screening and
      all following visits.

      Radiographs (flexion-extension) or MRI or CT scans of the cervical spine will be performed
      at Screening and at Week 49. Clinical laboratory tests, Electrocardiograms (ECG) will be
      performed at Screening, Baseline, Weeks 25 and 49 visits. Blood samples will be collected at
      Baseline, every 24 weeks, and at the last scheduled visit or at the early termination visit
      for TAb and NAb  testing. NAb will not be performed if TAb is negative. Samples for Total
      IgE will be collected at Baseline and stored for testing. For patients who experience a
      severe infusion associated reaction (IAR), experience an IAR requiring cessation of
      infusion, anaphylaxis or a serious hypersensitivity event, shortly after cessation of the
      infusion, the Baseline total IgE sample will be analyzed and additional blood samples for
      total IgE and drug-specific IgE testing will be drawn and run. Immediate testing for total
      IgE will be taken shortly after cessation of the study drug infusion. Drug-specific IgE will
      also be tested, but must be collected no sooner than 8 hours post infusion and no later than
      just before the next scheduled infusion the following week due to rhGALNS interference with
      the detection assay. A sample taken the day after the IAR, anaphylactic or serious
      hypersensitivity event would be preferred but may not be practical. If the sample is
      positive, the extra volume of serum may be used to further characterize the drug-specific
      IgE assay. As patients may experience hypersensitivity reactions associated with the
      administration of BMN 110, all patients will be pretreated with an appropriate dose of
      antihistamine medication approximately 30 minutes to 1 hour prior to infusion. Antipyretic
      medications may also be given at the discretion of the Investigator. On infusion days, vital
      signs will be measured at a minimum of: immediately before (less than 30 minutes) the
      infusion, every 30 minutes for the first hour of the infusion, every hour for the remainder
      of the infusion, and immediately (less than 30 minutes) after the infusion. Patients will
      also be monitored by continuous pulse oximetry during infusion and for at least 60 minutes
      after the infusion is completed. AEs/SAEs and changes in concomitant medication will be
      recorded throughout the study. AEs/SAEs will be graded according to the National Cancer
      Institute (NCI)Common Terminology Criteria for Adverse Events (CTCAE).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety Analysis</measure>
    <time_frame>The study period during which all non-serious AEs and SAEs will be reported begins after informed consent is obtained and through 30 days after the last study visit or 30 days after the last drug infusion, whichever comes first.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The analyses of safety will include all patients who receive any study drug. All safety data will be summarized descriptively. All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). The incidence of AEs will be summarized by System Organ Class (SOC), Preferred Term (PT), relationship to study drug, and severity. Patient listings will be provided for SAEs, deaths, and AEs leading to study drug discontinuation, or study withdrawals. All AE summaries will include only treatment-emergent AEs (TEAEs) reported during the study period (AEs that occur after the first study drug infusion). Infusion-associated AEs will be summarized by SOC, PT and severity.
The following safety measures will be summarized descriptively: concomitant medications, clinical laboratory tests, vital signs, ECGs, immunogenicity results, analgesic medication use, results from routine physical examinations (including standard neurologic examinations), and cervical spine imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy Analysis</measure>
    <time_frame>Baseline, Week 25, Week 49 or Early Termination Visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy assessments and procedures are the duplicate endurance testing (6MW and 3MSC tests) at Baseline and at week 25 and 49. Samples for urine KS and urine creatinine will be collected at Baseline and every 24 weeks.
Anthropometric measurements, including standing height, length, sitting height, knee height (as clinically indicated), head circumference and weight, will be taken at Baseline and every 24 weeks.
Respiratory function tests (RFTs) for assessment of forced expiratory volume for 1 second (FEV1), forced inspiratory vital capacity (FIVC), forced vital capacity (FVC), and maximum voluntary ventilation (MVV) will be performed at Baseline and Weeks 25 and 49.  APPT (pain assessment tool), and the PedsQL (Pediatric Quality of Life Inventory) or SF-36Â® (QOL questionnaire for adult patients) will be done at Baseline, Week 25, and Week 49.  The Sleep Apnea Test will be done at Baseline, Week 25 and Week 49, if applicable.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Mucopolysaccharidosis IVA (Morquio A Syndrome)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMN 110</intervention_name>
    <other_name>recombinant human N-acetylgalactosamine-6-sulfatase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed with MPS IVA as confirmed by a documented GALNS enzymatic test (GALNS
             activity in affected range, beta-galactosidase and a second lysosomal sulfatase
             activity within normal range).

          2. Age 12 months or older.

          3. Willing and able to provide written, signed informed consent. Or, in the case of
             patients under the age of 18 (or other age as defined by regional law or regulation),
             provide written assent (if required) and have written informed consent, signed by a
             legally authorized representative, after the nature of the study has been explained,
             and prior to performance of research-related procedures.

          4. If sexually active, must be willing to use an acceptable method of contraception
             while participating in the study.

          5. If female, and of childbearing potential, must have a negative pregnancy test at
             Baseline and be willing to have additional pregnancy tests done during the study.
             Females considered not of childbearing potential include those who have been in
             menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening,
             or who have had total hysterectomy. Childbearing potential will be assessed by the
             investigator.

        Exclusion Criteria:

          1. Previous treatment with BMN 110.

          2. Has known hypersensitivity to any of the components of BMN 110.

          3. Major surgery within 3 months prior to study entry or planned major surgery during
             the 48-week treatment period.

          4. Prior bone marrow transplant (BMT) or hematopoietic stem cell transplant (HSCT).

          5. Is pregnant or breastfeeding at Baseline, or planning to become pregnant (self
             orpartner) at any time during the study. Patients who become pregnant during the
             study will be discontinued from the study.

          6. Has used any investigational product, or investigational medical device, within 30
             days prior to Baseline; or is required to use any investigational agent prior to
             completion of all scheduled study assessments.

          7. Has a concurrent disease or condition, including but not limited to, symptomatic
             cervical spine instability, clinically significant and/or progressive spinal cord
             compression, or severe cardiac disease that would interfere with study participation,
             or pose a safety risk, as determined by the Investigator.

          8. Has any condition that, in the view of the Investigator, places the patient at high
             risk of poor treatment compliance or of not completing the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kaustuv Bhattacharya</last_name>
      <phone>+61 (0)2 9845 3654</phone>
      <email>kaustuv.bhattacharya@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Kaustuv Bhattacharya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James McGill</last_name>
      <phone>+61 (0)7 3636 8176</phone>
      <email>Jim_McGill@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Anita Inwood</last_name>
      <phone>+61 (0)7 3636 9264</phone>
      <email>Anita_Inwood@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Jim McGill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Murdoch Childrens Research Institute and Royal Children's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Peters</last_name>
      <phone>+61 (0)3 8341 6257</phone>
      <email>heidi.peters@mcri.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Davidson</last_name>
      <phone>+61 (0)3 9345 6437</phone>
      <email>Nicole.Davidson@rch.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Heidi Peters</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shanti Balasubramaniam</last_name>
      <phone>+61 (0)8 934 0222</phone>
    </contact>
    <investigator>
      <last_name>Shanti Balasubramaniam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pain and Anaesthesia Research Clinic, Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5OOO</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Ketteridge, MD</last_name>
      <phone>+61 882225422</phone>
      <email>david.ketteridge@health.sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>DAVID KETTERIDGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 28, 2013</lastchanged_date>
  <firstreceived_date>September 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis IV</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
